Can Fractyl Labs and Cala Health go where only drugs have gone before? episode artwork

EPISODE · Aug 21, 2020 · 50 MIN

Can Fractyl Labs and Cala Health go where only drugs have gone before?

from DeviceTalks Podcast Network · host DeviceTalks Podcast Network

In this week’s episode of the DeviceTalks Weekly podcast, co-hosts Tom Salemi, editorial director of DeviceTalks, and Chris Newmarker, executive editor of life sciences, review this week's Top 5 medtech stories, aka “Newmarker’s Newsmakers,” with news coming from CureVac, Avail Medsystems, ClearMask, Thermo Fisher and Bayer. We also hear from two executives from Fractyl Laboratories — CEO Dr. Harith Rajagopalan and CFO Lisa Davidson — about its recent $55 million Series E round of financing and the strides they're making in developing a device to treat diabetes. In a second interview, Cala Health CEO Renee Ryan gives us an update on the Cala Trio’s clinical success and how the start-up is working through COVID-19. Finally, Chris and Tom hint at an upcoming event for the DTW community.

Episode metadata supplied by the publisher feed · Published Aug 21, 2020

Embed this episode

NOW PLAYING

Can Fractyl Labs and Cala Health go where only drugs have gone before?

0:00 50:41

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of DeviceTalks Podcast Network?

This episode is 50 minutes long.

When was this DeviceTalks Podcast Network episode published?

This episode was published on August 21, 2020.

Can I download this DeviceTalks Podcast Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!